Media stories about Aclaris Therapeutics (NASDAQ:ACRS) have been trending somewhat positive on Sunday, Accern Sentiment Analysis reports. The research group identifies negative and positive press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Aclaris Therapeutics earned a news impact score of 0.11 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 46.2030967449406 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
A number of equities research analysts have issued reports on the stock. Zacks Investment Research raised shares of Aclaris Therapeutics from a “hold” rating to a “buy” rating and set a $31.00 price target on the stock in a report on Tuesday, October 10th. BidaskClub raised shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, December 29th. Cantor Fitzgerald set a $50.00 price target on shares of Aclaris Therapeutics and gave the stock a “buy” rating in a report on Wednesday, October 4th. Finally, ValuEngine lowered shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, September 12th. Two analysts have rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. Aclaris Therapeutics has an average rating of “Hold” and a consensus price target of $39.20.
Shares of Aclaris Therapeutics (NASDAQ:ACRS) opened at $24.63 on Friday. Aclaris Therapeutics has a 12-month low of $21.32 and a 12-month high of $33.25. The company has a market cap of $759.47, a PE ratio of -11.40 and a beta of 1.96.
Aclaris Therapeutics (NASDAQ:ACRS) last posted its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.63) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.86) by $0.23. The company had revenue of $0.68 million during the quarter, compared to analysts’ expectations of $2.00 million. analysts predict that Aclaris Therapeutics will post -2.59 EPS for the current year.
TRADEMARK VIOLATION NOTICE: “Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Aclaris Therapeutics (ACRS) Stock Price” was originally published by Equities Focus and is the property of of Equities Focus. If you are viewing this report on another site, it was stolen and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://www.equitiesfocus.com/2018/01/07/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-aclaris-therapeutics-acrs-stock-price.html.
Aclaris Therapeutics Company Profile
Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.